Pentren

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pentren

Pentren is a prescription-only pharmaceutical containing the active ingredient Omeprazole, primarily defined by its role as a potent Gastric Acid Secretion Inhibitor. The medication's identity is rooted in its highly specific mechanism of action, making it a foundational treatment in its pharmacological class.


Quick Facts: Pentren Identity

Property Description
Active ingredient Omeprazole
Form Delayed-Release Capsules
Pharmacological class Proton Pump Inhibitor (PPI)
Common use Gastric Acid Control
Origin Synthetic Compound

What is Pentren? An Identity and Classification Overview

Pentren: Defining the Pharmaceutical Entity and Active Composition

Pentren is a pharmaceutical preparation whose sole active ingredient is Omeprazole, a substance clinically recognized for its efficacy and included on the list of essential medicines. This medicine is a synthetic compound derived from the Substituted Benzimidazole chemical class. The unique feature of Pentren's formulation, setting it apart from some immediate-release analogues, is its presentation as Delayed-Release Capsules containing Enteric-Coated Pellets for Oral Administration. This specialized design ensures the Omeprazole remains protected from degradation by stomach acid, guaranteeing its effective delivery to the intended absorption site.

Classification: Pentren as a Proton Pump Inhibitor (PPI)

The presence of Omeprazole places Pentren firmly in the Pharmacological Class known as Proton Pump Inhibitors (PPIs). This classification identifies it as a highly effective Gastric Acid Secretion Inhibitor that functions as a prodrug. Omeprazole's mechanism is distinguished by the fact that it forms a permanent bond to the H^+K^+-ATPase enzyme, otherwise known as the proton pump. This classification is due to its specific, irreversible inhibition of the final step of acid secretion.

General Purpose: The Anti-Secretory Utility

The fundamental purpose of Pentren is to provide a profound and sustained reduction of acidity across the gastric environment. This reliable action of acid secretion blockade is the drug's core utility, typically used in scenarios where continuous, powerful acid suppression is necessary. The patient-relevant benefit is that this medicine consistently controls and maintains low levels of acidity within the gastric lumen, which helps reduce the acid burden that contributes to related issues.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Pentren?

Possible Side Effects and Safety Information

The safety profile of Pentren (Omeprazole) is structured according to regulatory classifications, detailing known adverse reactions and specific constraints documented in official government prescribing information. Adverse reactions are grouped by frequency and the body system affected.

Officially Classified Adverse Reactions

Classification Common Reactions (Affecting 1% to 10% of users) Uncommon Reactions (Affecting 0.1% to 1% of users)
Adverse Effects Headache, Abdominal pain, Diarrhea, Flatulence, Nausea, Vomiting Insomnia, Dizziness, Vertigo, Dermatitis, Rash, Urticaria, Increased liver enzymes

Documented Serious Adverse Reactions and Constraints

Regulatory documents list several serious adverse reactions, which are typically rare but clinically significant. These include Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome, severe Hypersensitivity Reactions (e.g., Anaphylaxis), and Acute Tubulointerstitial Nephritis (AIN).

Time-Related Safety Patterns: Certain effects are explicitly associated with prolonged use. Long-term administration may be linked to an increased risk of bone fracture of the hip, wrist, or spine. Additionally, extended therapy, particularly beyond one year, is associated with the formation of Fundic Gland Polyps and may lead to conditions like Hypomagnesemia and Cyanocobalamin (Vitamin B-12) deficiency.

Safety Constraints: Safety information highlights that Omeprazole use may be associated with an increased risk of Clostridioides difficile-associated diarrhea (CDAD). The medication can also cause increases in Chromogranin A (CgA) levels, which may interfere with diagnostic investigations for neuroendocrine tumors. Specific safety notes address that the symptomatic response to this medicine does not rule out the presence of gastric malignancy.

Overdose and Emergency Response

Pentren (Omeprazole) overdose information is strictly compiled from official regulatory sources and describes the documented manifestations and mandatory emergency procedures.

Acute overdosage may present with symptoms that are typically classified as mild and transient. The clinical manifestations documented in official labeling primarily affect the gastrointestinal and nervous systems. These include gastrointestinal effects such as nausea, vomiting, abdominal pain, diarrhea, and flatulence. Reported central nervous system effects are headache, confusion, somnolence (drowsiness), dizziness, and blurred vision. Other documented physical signs include tachycardia (increased heart rate), increased sweating, dryness of the mouth, and flushing.

In the event of a suspected or actual overdose, official regulatory guidance requires the patient to seek immediate medical attention. Contacting emergency services or a designated Poison Control Center must occur promptly. The established regulatory management strategy is to provide symptomatic and supportive treatment. This procedural approach is necessary because official prescribing information confirms that no specific antidote is known for Omeprazole overdosage. Management involves clinical observation and monitoring, with supportive care tailored to the patient’s clinical presentation. No specific, differentiated management instructions for populations such as those with hepatic impairment are documented within the overdose section of the official label.

Therapeutic Uses of Pentren

Pentren (Omeprazole) is commonly used to help manage conditions and symptoms related to physical discomfort caused by excessive or misplaced stomach acid. It is applied across domains where additional symptomatic support is needed to assist with healing and supports general well-being during symptomatic phases.

This medication is considered relevant for managing Gastroesophageal Reflux Disease (GERD) and erosive esophagitis. It may be part of symptomatic management for active gastric and duodenal ulcers and is commonly used to help with pathologic hypersecretory conditions, such as Zollinger-Ellison Syndrome (ZES). It is also relevant in combination therapies applied in addressing Helicobacter pylori infection and in clinical settings that involve acute or unstable symptom patterns for patients at higher risk.

“Pentren is used for managing symptoms that create noticeable physiological strain, such as frequent, burning heartburn and the pain associated with acid-related lesions, contributing to improved comfort during periods of heightened symptoms.”

It provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability and easing the overall symptom load.


Quick Fact: Relief for Acid-Related Strain
Pentren is commonly used to help manage symptoms linked to severe acid exposure, including heartburn, acid regurgitation, and pain associated with tissue irritation in the esophagus and stomach.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Pentren? (Omeprazole)

The eligibility criteria for using Pentren (Omeprazole) are strictly defined by regulatory authorities and based on specific patient populations and conditions.

Populations for Whom Use is Contraindicated

Classification Population/Condition
Absolute Ban Patients with known hypersensitivity to Omeprazole or other substituted benzimidazoles (the drug class).
Absolute Ban Use is prohibited in patients concurrently receiving the antiretroviral drug nelfinavir.

Age- and Condition-Based Eligibility

Population Group Eligibility Status (Regulatory Wording)
Adults Established for all approved indications.
Children (1 to 16 years) Established for specific indications like GERD and erosive esophagitis.
Infants (< 1 year) Safety and effectiveness have not been established.
Severe Hepatic Impairment Use requires caution and may necessitate a lower dose.
Renal Impairment No dose adjustment is needed.
Pregnancy/Lactation Can be used; not likely to influence the child at therapeutic doses.

Use of Pentren requires that gastric malignancy be excluded before starting treatment for a gastric ulcer. These regulations strictly define who is eligible, who is not eligible, and under what conditional terms the medicine may be used.

What should I know about interactions with other medicines?

Pentren (Omeprazole) has officially documented interaction patterns primarily structured by its inhibition of the CYP2C19 enzyme and its ability to inhibit gastric acid secretion, which alters the pH environment necessary for drug absorption.


Contraindicated and Restricted Combinations

Co-administration with the antiretrovirals Nelfinavir and Rilpivirine is formally contraindicated due to the risk of significantly reduced plasma concentrations of these medicines. Concomitant use with the anti-platelet medicine Clopidogrel is strongly discouraged as Omeprazole diminishes its therapeutic activity, an effect noted even when administration is separated in time.


Pharmacokinetic and Pharmacodynamic Effects

Pentren increases the systemic exposure and prolongs the elimination of CYP2C19 substrates, including Warfarin, Phenytoin, and Diazepam, necessitating careful consideration. The reduction in gastric acidity reduces the absorption of Ketoconazole and Itraconazole, while increasing the exposure of Digoxin. Separately, treatment with Omeprazole must be interrupted for a period (at least five days) before measuring Chromogranin A (CgA) levels, as the medicine can interfere with this diagnostic test.


Interactions with Other Substances

The herbal product St. John's Wort and the medicine Rifampin are noted to reduce the plasma concentration of Omeprazole itself. Long-term use may also lead to reduced absorption of Vitamin B12 (Cyanocobalamin).

Mechanism of Action

Pentren (Omeprazole) exerts its physiological consequence through an irreversible molecular blockade targeting the final step of acid secretion. Its mechanism is defined by distinct and interconnected biological domains.


Irreversible Molecular Blockade of the Proton Pump

Pentren functions as a prodrug that is selectively activated only in the highly acidic environment of the stomach's parietal cells. Its activated form then forms a permanent covalent bond with the H^+K^+-ATPase enzyme (the proton pump), resulting in the irreversible inhibition of this enzyme. This action prevents the parietal cell from releasing hydrogen ions, effectively blocking the final common pathway of acid secretion and resulting in a substantial physiological reduction in stomach acidity.


⏳ Sustained Action Governed by Enzyme Turnover

Due to the permanent nature of the blockade, the duration of the suppression of acid output is not controlled by how quickly the drug is cleared from the bloodstream. Instead, the effect profile relies on the slow physiological turnover rate of the parietal cells. Full restoration of acid secretion only occurs when the stomach lining synthesizes and incorporates new, unblocked H^+K^+-ATPase enzyme molecules, contributing to the sustained duration of the suppression of acid output.

Dosage and Administration Information

Instruction Map: How to use Pentren — Official Administration Guidelines

The administration of Pentren is guided by strict requirements to ensure patient safety and drug efficacy. As an injectable product, it is administered solely by a healthcare professional in a controlled setting.

Administration Scope Official Regulatory Guideline
Route of Administration Intravenous (IV) infusion.
Dosing Schedule 10 mg/kg of patient body weight, administered once every 4 weeks.
Timing in Relation to Meals Administration is independent of food consumption.
Age-Group Rules Approved for patients 18 years and older. Patients over 75 years of age require a dose reduction to 5 mg/kg.
Missed-Dose Rules If a scheduled dose is missed, administer the dose as soon as possible. The next dose should be scheduled 4 weeks after the date of the missed-dose administration.

Preparation and Procedural Steps

Preparation for infusion involves two distinct, critical steps:

  1. Reconstitution: The Pentren vial must be reconstituted by introducing 5 mL of Sterile Water for Injection, followed by gentle swirling until the powder is fully dissolved. Vigorous shaking is explicitly prohibited.
  2. Dilution: The reconstituted solution must then be diluted into 250 mL of 0.9% Sodium Chloride Injection for the final infusion mixture.

The final solution must be administered via IV infusion, maintaining an infusion rate that does not exceed 10 mL/minute over the entire administration duration. This process requires continuous monitoring by a healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pentren

This overview summarizes the types of clinical research conducted for Pentren (Omeprazole), including how findings have been measured and what areas of study still contain limitations or uncertainties, according to official regulatory and scientific literature.


Evidence for Management of Acid Reflux (GERD) and Esophageal Healing (EE)

The research utilizes various study types, including short-term Randomized Controlled Trials (RCTs). These studies explore how symptoms change over time, focusing on outcomes related to physical discomfort, such as the frequency and intensity of heartburn. For Erosive Esophagitis, research examined the endoscopic healing rate, where findings reported the proportion of participants whose esophageal lesions were observed to resolve. The studies focused on short, defined time intervals, typically 4 to 8 weeks. Long-term effects are not fully established regarding outcomes related to symptom or lesion recurrence over periods significantly longer than one year, as the follow-up durations were limited in the controlled RCT setting.


Evidence for Peptic Ulcer Healing and H. pylori Eradication

Pentren was evaluated in studies focusing on the acute treatment of Gastric and Duodenal Ulcers (PUD). Researchers focused on the ulcer healing rate, confirmed by endoscopy, along with monitoring outcomes related to physical discomfort and pain. The medicine was also studied for its application in treating the bacterial infection Helicobacter pylori as a component of combination therapies. Research examined the eradication rate, and studies observed that successful eradication was associated with patterns related to lower rates of ulcer recurrence. Since much of the current evidence involves combination therapy, data for certain groups remain insufficient when attempting to isolate the medicine’s role in ulcer healing outside of an infection context.


Key Gaps and Remaining Research Uncertainties

The broader evidence landscape examines symptom patterns, but several research limitations frames persist across all indications. Controlled research on the consequences of continuous, multi-year administration is primarily observational, not comparative, meaning long-term effects are not fully established. Furthermore, subgroup findings are uncertain; data for certain groups, such as those with specific comorbidities or rare forms of acid-related disease, remain insufficient. Research does not determine whether an individual will respond similarly, as results apply only to the populations studied.

Key Studies & References

  1. Omeprazole - StatPearls (NCBI Bookshelf)
  2. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis (PMC/NIH)

Frequently Asked Questions (FAQ)

Common questions about Pentren (FAQ)

Q: Are there any common over-the-counter medicines that should not be taken with Pentren?

A: Official product information suggests speaking with a healthcare provider or pharmacist about all other medicines a person is taking, including those bought over-the-counter. This is because acid-reducing medicines like Pentren may interact with the way some other non-prescription drugs are absorbed or processed by the body. Consultation can help clarify potential interactions and support informed use of all medications.


Q: Does taking Pentren require regular blood tests or monitoring?

A: For individuals receiving long-term therapy, typically for a year or longer, healthcare professionals may consider monitoring certain health indicators. Monitoring may be considered for checking magnesium levels, as prolonged use has been associated with a rare risk of low magnesium in the blood (Hypomagnesemia). Decisions about monitoring frequency are determined by the treating healthcare professional.


Q: Can Pentren affect my ability to drive or operate machinery?

A: Official safety information states that certain uncommon side effects, such as dizziness and vertigo, have been reported by some users. If a patient experiences these effects or difficulty sleeping (insomnia), individuals are advised to exercise appropriate caution when driving or operating heavy machinery. This is a standard advisory based on the potential for reduced alertness.


Q: How long do most people stay on Pentren treatment?

A: The duration of treatment is guided by the specific condition being addressed. For common over-the-counter use for frequent heartburn, a course is typically 14 days. When prescribed by a doctor for conditions like ulcers or erosive esophagitis, therapy is often limited to 4 to 8 weeks, though certain rare conditions may require sustained, long-term use.


Q: What should I do if I notice a skin rash after starting Pentren?

A: While a common skin rash is listed as an uncommon side effect, regulatory documents warn that Pentren may rarely cause very severe skin reactions. If a severe rash, blistering of the skin, or other signs of an allergic reaction occur, official warnings advise that use should be stopped immediately. Contacting a healthcare professional is necessary for guidance regarding any severe or concerning skin changes.


Q: What is the expected long-term outcome when taking Pentren?

A: For specific chronic conditions, the intended goal of long-term therapy is the maintenance of symptom control and healing. However, official regulatory warnings indicate that continuous, long-term administration may be associated with certain risks. These risks include an increased risk of bone fracture, formation of Fundic Gland Polyps, and potential Vitamin B12 deficiency.


Q: How quickly does Pentren typically start working?

A: Official information clarifies that Pentren is not an immediate-relief medicine, as its mechanism of action requires time to take effect. The full acid-reducing effect is generally achieved within 1 to 4 days of initiating therapy.


Q: Does Pentren cause weight gain or weight loss?

A: Neither weight gain nor weight loss is explicitly listed as a common or uncommon side effect of Pentren in official regulatory documents. However, unexplained weight loss is listed as a warning sign that could be related to a more serious underlying condition, and consulting a healthcare provider is noted as important if it occurs.


Q: Is it normal to feel tired when starting Pentren?

A: While general tiredness (fatigue) is not listed as a common side effect, official reports link it to a rare long-term condition called Hypomagnesemia, or low magnesium levels. This is a side effect associated with prolonged use of the drug. If unusual or persistent tiredness is experienced, regulatory information suggests this should be brought to the attention of a healthcare professional.


Q: Is there a generic version of Pentren available?

A: Yes, the active ingredient in Pentren, which is omeprazole, is available as a generic medicine. Regulatory documents confirm that omeprazole is available in various generic forms, including over-the-counter options, as well as prescription capsules and tablets.


Q: Is Pentren considered a controlled substance?

A: No, Pentren is categorized as a prescription-only pharmaceutical, but it is not classified as a controlled substance under official regulatory definitions in the United States. This classification indicates it does not have the same potential for abuse or dependence as scheduled drugs.


Q: Are the side effects of Pentren permanent?

A: Official information suggests that many adverse effects, including some rare, severe conditions associated with long-term use, may be reversible upon discontinuation of the medicine. For instance, low magnesium levels (Hypomagnesemia) often normalize once the drug is stopped. Regulatory information suggests that most common side effects typically resolve.


Q: Does Pentren have a 'Black Box' warning?

A: Based on current regulatory labeling from the FDA, Omeprazole (Pentren) does not carry a Boxed Warning (often referred to as a Black Box Warning). While the official label contains various warnings and precautions, none of them require this specific, most serious level of regulatory highlighting.


Q: Can Pentren affect blood pressure?

A: The medicine is not typically known to directly cause changes in blood pressure. However, official interaction data notes that Pentren may interact with the metabolism of certain blood pressure medications, which could potentially alter the effect of that co-administered drug.


Q: Is it possible to become dependent on Pentren?

A: Official regulatory sources do not classify Pentren as a medicine that causes physical or psychological dependence. Official labeling notes that abruptly stopping the medicine, however, especially after long-term use, can lead to a physiological effect called rebound acid hypersecretion, causing a temporary increase in stomach acid.


Q: If I stop taking Pentren, will I experience withdrawal symptoms?

A: While Pentren does not cause traditional withdrawal symptoms, regulatory knowledge acknowledges a physiological phenomenon known as rebound acid hypersecretion. If the medicine is stopped abruptly after a long period of use, this can lead to a temporary increase in acid production, resulting in a return or worsening of acid-related symptoms.


Q: Do people typically take Pentren in the morning or evening?

A: For the treatment of frequent heartburn (OTC use), the official instructions advise taking the medicine once daily. This dose is typically swallowed whole before eating in the morning. This timing is often utilized to allow the medicine to be active before the body begins its typical cycle of acid production.


Q: Why do official sources list so many possible side effects for Pentren?

A: Official regulatory bodies require pharmaceutical companies to document all adverse events that were reported in clinical trials and during post-marketing surveillance. This comprehensive listing is mandated to provide healthcare providers and patients with the most complete picture possible of the known risk profile, regardless of the frequency of the side effect.


Q: How is the safety of Pentren monitored after it is released to the public?

A: The safety of Pentren is continuously tracked through a process called post-marketing surveillance. This global system relies on the reporting of any suspected adverse reactions by healthcare professionals, patients, and manufacturers to official regulatory agencies like the FDA or EMA. This ensures the safety profile remains up-to-date throughout the drug's use.


Q: Does Pentren interact with birth control pills?

A: The official regulatory documents concerning drug interactions do not list oral contraceptives (birth control pills) as a known or significant interaction that requires a contraindication or dose adjustment. However, regulatory principles recommend checking with a healthcare professional regarding any combination of medicines.


Q: What if I drink alcohol while taking Pentren?

A: Official regulatory documents generally do not note a specific drug interaction between Pentren (Omeprazole) and alcohol consumption. Nevertheless, consultation with a healthcare professional is suggested, especially if there are underlying health conditions that are related to alcohol use, such as liver disease.


Q: Is Pentren a new medicine, or has it been around for a while?

A: The active ingredient in Pentren, Omeprazole, is not a new medicine. It was the first drug introduced in its pharmacological class and has been available on the market since 1988, making it a well-established and foundational treatment for acid-related conditions.


Q: Do many people stop taking Pentren due to side effects?

A: Official safety data indicates that adverse effects like headache, diarrhea, and skin rashes have, in some instances, led to the requirement for treatment discontinuation. However, regulatory documents do not provide specific data or statistics regarding the overall rate of patients who stop taking the medicine due to side effects.

How should Pentren be stored and disposed of?

How to Store and Dispose of Pentren (Omeprazole)

The storage and disposal of Pentren must follow specific regulatory instructions to protect the medicine's stability and prevent accidental harm.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 to 25 C).
Container Keep in the original container and maintain a tightly closed seal.
Protection The product must be protected from moisture and humidity.
Child Safety Mandatory instruction to keep the product out of the sight and reach of children.

Disposal Instructions

Official guidelines state that unused or expired Pentren should be disposed of through a drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance, seal it in a bag, and place it in the household trash. Do not dispose of this medicine via wastewater or household sewers.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pentren found in:

A-Z Index: